CIRCULATING microRNAs: PROSPECTS OF USE FOR EARLY DIAGNOSTICS AND MONITORING OF TUMOR PROCESS
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-21-3-2019-g.8001Keywords:
circulating microRNAs, diagnosis, drug therapy, efficacy, malignancies, prognosisAbstract
MicroRNAs are small non-coding RNAs of 21–22 nucleotides in length that are involved in the post-transcriptional regulation of gene expression. Today, more than 2500 microRNAs are already known and this list is constantly growing. Much of the research in recent years is devoted to the study of changes in the expression of microRNAs in the occurrence of various pathological conditions of the organism, including cancer. The results of our own studies and the literature on the possibility of using microRNAs as diagnostic and prognostic markers of the most common malignancies are analyzed and summarized. The prospects of using panels of circulating microRNAs to monitor the course of the tumor process and to determine the sensitivity of tumors of different histogenesis to drug treatment are discussed. To date microRNAs have been identified with high diagnostic sensitivity and specificity for most malignancies; if successfully passed clinical trials, the determination of such miRNAs can be put into medical practice as a minimally invasive test.
References
Altoe M, Gunther J, Lim E, et al. Neoadjuvent therapy monitoring in breast cancer patients with diffuse optical tomography. Clin Translational Biophotonics 2018; CTu4B-6 (https://doi.org/10.1364/TRANSLATIONAL.2018.CTu4B.6).
Larrea E, Sole C, Manterola L, et al. New concepts in cancer biomarkers: circulating miRNAs in liquid biopsies. Int J Mol Sci 2016; 17 (5): 627.
Chekhun VF, Lukianova NY, Borikun TV, et al. The clinical significance of tumor miR-122,-155,-182, and-200b expression in patients with breast cancer. Science and Innovation 2017; 13 (5): 63–9 (in Ukrainian).
Chekhun VF, Boroday NV, Yurchenko OV. MicroRNA and tumor process. Oncology 2012; 15 (2): 136–40.
Lekka E, Hall J. Noncoding RNAs in disease. FEBS lett 2018; 592 (17): 2884–900.
Backes C, Meese E, Keller A. Specific miRNA disease biomarkers in blood, serum and plasma: challenges and prospects. Mol Diagnosis Ther 2016; 20 (6): 509–18.
Matsuzaki J, Takahiro O. Circulating microRNAs and extracellular vesicles as potential cancer biomarkers: a systematic review. Int J Clin Oncol 2017; 22 (3): 413–20.8. Creugny A, Fender A, Pfeffer S. Regulation of primary micro RNA processing. FEBS Lett 2018; 592 (12): 1980–96.
Lee RC, Rhonda LF, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75 (5): 843–54.
Lagos-Quintana M, Rauhut R, Meyer J, et al. New microRNAs from mouse and human. RNA 2003; 9 (2): 175–9.
Chen X, Yan CC, Zhang X, et al. WBSMDA: within and between score for MiRNA-disease association prediction. Sci Reports 2016; 6: 21106.
Li JQ, Rong ZH, Chen X, et al. MCMDA: Matrix completion for MiRNA-disease association prediction. Oncotarget 2017; 8 (13): 21187.
Gu C, Liao B, Li X, Li K. Network consistency projection for human miRNA-disease associations inference. Sci Reports 2016; 6: 36054.
Vishnoi A, Rani S. MiRNA biogenesis and regulation of diseases: an overview. MicroRNA Profiling. Humana Press, New York, 2017: 1–10.
Catalanotto C, Cogoni C, Zardo G. MicroRNA in control of gene expression: an overview of nuclear functions. Int J Mol Sci 2016; 17 (10): 1712.
Wilczynska A, Bushell M. The complexity of miRNA-mediated repression. Cell Death Differentiation 2015; 22 (1): 22.
Lukianova N, Borikun T, Yalovenko T, Chekhun V. Role of mirna-122 and mirna-200b in intratumor heterogeneity formation and human breast cancer prognosis. International. J Current Res Rev 2016; 8 (17): 50.
Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK. miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discovery 2016; 6 (3): 235–46.
Calin GA, Dumitru CD, Shimizu M. et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524–9.
Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16–1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010; 17 (1): 28–40.
Reddy KB. MicroRNA (miRNA) in cancer. Cancer Cell Int 2015; 15 (1): 38.
Irmak-Yazicioglu MB. Mechanisms of microRNA deregulation and microRNA targets in gastric cancer. Oncol Res Treat 2016; 39 (3): 136–9.
Zadvornyi TV, Lukianova NY, Borikun TV, Chekhun VF. Effects of exogenous lactoferrin on phenotypic profile and invasiveness of human prostate cancer cells (DU145 and LNCaP) in vitro. Exp Oncol 2018; 40 (3): 184–9.
Chekhun VF, Lukianova NY, Borikun TV, et al. Artemisinin modulating effect on human breast cancer cell lines with different sensitivity to cytostatics. Exp Oncol 2017; 39 (1): 25–9.
Cheng G. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Delivery Rev 2015; 81: 75–93.
Kosaka N, Haruhisa I, Takahiro O. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010; 101 (10): 2087–92.
Nakamura K, Sawada K, Yoshimura A, et al. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 2014; 11 (3): 145.
Сuk K, Zucknick M, Heil J, et al. Circulating microRNA in plasma as early detection markers for breast cancer. Int J Cancer 2013; 132: 1602–12.
Madhavan D, Zuknick M, Wallwiener M, et al. Circulating miRNA as surrogate markers for circulating tumor cells and prognostric markers in metastatic breast cancer. Cancer Res 2012; 18: 5972–5981.
Cheng HH, Mitchell PS, Kroh EM, et al. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS ONE. 2013; 8 (7): e69239.
Jia W, Wu Y, Zhang Q, et al. Identification of four serum microRNAs from a genome‑wide serum microRNA expression profile as potential non‑invasive biomarkers for endometrioid endometrial cancer. Oncology Lett 2013; 6 (1): 261–7.
Yang C, Wang C, Chen X, et al. Identification of seven serum microRNA from a genome wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer 2013; 132: 116–27.
Liu AM, Yao TJ, Wang W, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2012; 2 (2): e000825.
Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18 (10): 997.
Kisseljov FL. MicroRNAs and cancer. Mol Biol 2014; 48 (2): 197–206.
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (6): 394–424.
Staren’kyj VP, Sukhyina OM, Byilozor NV, et al. The choice of irradiation volume radiotherapy in sequential chemoradiation therapy of non-small-cell lung cancer. Ukr J Radiol 2015; 23 (2): 142–146 (in Ukrainian).
Remennyk ОІ, Varyvonchyk DV. Morpho-functional criteria of risk development and prevention of neoplasms in bronchi and lungs among occupational patients exposed to dust, containing crystal silica. Ukr J Occupation Healht 2010; 4 (24): 51–7 (in Ukrainian).
Zhang H, Mao F, Shen T, et al. Plasma miR-145, miR-20a, miR-21 and miR-223 as novel biomarkers for screening early-stage non-small cell lung cancer. Oncol Lett 2017; 13: 669–76.
Arab A, Karimipoor M, Irani S, et al. Potential circulating miRNA signature for early detection of NSCLC. Cancer Genet 2017; 216–217: 150–8.
Wang H, Peng R, Wang J, et al. Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. Clin Epigenet 2018; 10 (1): 59.
Healy N, Heneghan H, Muller N, et al. Systemic microRNA as potential biomarkers in cancer. Int J Cancer 2013; 131: 2265–71.
Mayevskyi OY. Modern methods of diagnosis using oncomarkers, specific immunotherapy. Rep Vinnytsia Nat Med Univer 2014; 18 (2): 635–40.
Hamam R, Ali AM, Alsaleh KA, et al. MicroRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. Sci Rep 2016; 6: 25997.
Chan M, Liaw CS, Ji SM, et al. Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res 2013; 19: 4477–87.
Lukianova N, Borikun T, Yalovenko T, et al. Role of miRNA-122 and miRNA-200b in intratumor heterogeneity formation and human breast cancer prognosis. Int J Curr Res Rev 2016; 8 (17): 50.
Chekhun VF, Lukianova NY, Chekhun SV, et al. Method for non-invasive determination of TNBC in patients. Health Newsletter 190–2016.
Heneghan HM, Miller N, Kelly R, et al. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 2010; 15: 673–682.
Pospekhova NI, Poyarkov SV, Zenit-Zhuravleva EG, et al. Expression analysis of microRNAs for the diagnosis and prognosis of breast cancer. Malignant Tumours 2012; 2 (2): 90–97 (in Russian).
Cancer in Ukraine, 2016–2017. Incidence, mortality, activities of oncological service. Bulletin of national cancer registry of Ukraine, № 19. Edit. Kolesnik OO, К., 2018, 131 p.
Shcherbina OV, Sakalo VS. MRТ, CT and radionuclide diagnosis in diagnosis of prostate cancer and metastases. Oncology 2010; 12 (1): 50–55.
Cat A, Köken T, Karalar M. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4–10 ng/mL: Diagnostic efficacy of MicroRNA-141. Clin Cancer Investig J 2017; 6: 10–4.
Mahn R, Heukamp LC, Rogenhofer S, et al. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011; 77 (5): 1265.e9–16.
Guzel E, Karatas OF, Semercioz A, et al. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer. Int J Cancer 2015; 136 (4): 875–79.
Zadvornyi TV, Borikun TV, Lukianova NYu, et al. Expression of miRNA-126, -205 and -214 in benign and malignant neoplasms of the prostate gland: possible diagnostic and prognostic significance. Oncology 2018; 21 (1): 10–16 (in Ukrainian).
Lukashenko AV, Boiko AV, Rozumeyko IV, Koshubarova MV. Review of IV version of Japanese gastric cancer treatment guidelines. Clin Oncol 2017; 3 (27): 11–21 (in Ukrainian).
Liu HS, Xiao HS. MicroRNAs as potential biomarkers for gastric cancer. World J Gastroenterol 2014; 20 (34): 12007–12017.
Li C, Li JF, Cai Q, et al. MiRNA-199a-3p: A potential circulating diagnostic biomarker for early gastric cancer. J Surg Oncol 2013; 108 (2): 89–92.
Li X, Luo F, Li Q, et al. Identification of new aberrantly expressed miRNAs in intestinal-type gastric cancer and its clinical significance. Oncol Rep 2011; 26: 1431–9.
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65 (2): 87–108.
Coburn SB, Bray F, Sherman ME, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer 2017; 140 (11): 2451–60.
Resnick KE, Alder H, Hagan JP, et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009; 112 (1): 55–9.
Zhang S, Lu Z, Unruh AK, et al. Clinically relevant microRNAs in ovarian cancer. Mol Cancer Res 2015; 13: 393–401.
Zheng H, Zhang L, Zhao Y, et al. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS ONE 2013; 8: e77853.
Corney DC, Hwang C-I, Matoso A, et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 2010; 16: 1119–28.
Lee C-H, Subramanian S, Beck AH, et al. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS ONE 2009; 4: e7314.
Hamakawa T, Kukita Y, Kurokawa Y, et al. Monitoring gastric cancer progression with circulating tumour DNA. Brit Jcancer 2015; 112 (2): 352–6.
Klein-Scory S, Maslova M, Pohl M, et al. Significance of liquid biopsy for monitoring and therapy decision of colorectal cancer. Translational Oncol 2018; 11 (2): 213–20.
Fan L, Li B. A serum microRNA expression signature for radiosensitivity of non-small cell lung cancer. Ann Oncol 2018; 29 (8): mdy269–178.
Fadejeva I, Olschewski H, Hrzenjak A. MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas. Oncotarget 2017; 8 (70): 115754–73.
Jung J, Wagner V, Körner C. MicroRNAs in therapy resistance of breast cancer. EMJ Oncol 2016; 4 (1): 103–12.
Zhao R, Wu J, Jia W, et al. Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie 2011; 34 (12): 675–80.
Jung EJ, Santarpia L, Kim J, et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 2012; 118 (10): 2603–14.
Wang XX, Ye FG, Zhang J, et al. Serum miR-4530 sensitizes breast cancer to neoadjuvant chemotherapy by suppressing RUNX2. Cancer Management Res 2018; 10: 4393–400.
Li Q, Liu M, Ma F, et al. Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel. PLoS One 2014; 9 (8): e104870.
Wang H, Tan G, Dong L, et al. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 2012; 7 (4): e34210.
Shao B, Wang X, Zhang L, et al. Plasma microRNAs predict chemoresistance in patients with metastatic breast cancer. Technology in Cancer Res Treat 2019; 18: 1–9.
Borikun TV. Connection of miR-320a and -200b expression with sensitivity to neoadjuvant polychemotherapyin Breast Cancer patients. Scientific and Practical Conference of Young Scientists «Fundamental Medicine: Integral approaches to cancer patients». Oncology 2019; 21 (1): 56–7.
Zhang HL, Yang LF, Zhu Y, et al. Serum miRNA-21: Elevated levels in patients with metastatic hormone‐refractory prostate cancer and potential predictive factor for the efficacy of docetaxel‐based chemotherapy. The Prostate 2011; 71 (3): 326–331.
Ribas J, Ni X, Haffner M, et al. miR-21: An androgen receptor-regulated microRNA that promotes hormone-dependent andhormone-independent prostate cancer growth. Cancer Res 2009; 69 (18): 7165–9.81. Lin HM, Castillo L, Mahon KL, et al. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Brit J Cancer 2014; 110 (10): 2462–71.
Kim CH, Kim HK, Rettig RL, et al. miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011; 4: 79–92.
Matuszcak C, Haier J, Hummel R, Lindner K. MicroRNAs: Promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential. World J Gastroenterol 2014; 20: 13658–13666.
Kim S, Han Y, Kim SI, et al. Tumor evolution and chemoresistance in ovarian cancer. NPJ Precis Oncol 2018; 2: 20–29.
Mihanfar A, Fattahi A, Nejabati HR. MicroRNA-mediated drug resistance in ovarian cancer. J Cell Physiol 2019; 234 (4): 3180–91.
van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 2010; 42 (8): 1282–90.
Eitan R, Kushnir M, Lithwick-Yanai G, et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol 2009; 114: 253–9.
Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793–801.
Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189–98.
Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64: 3753–6.
Xia Y, Zhu Y, Zhou X, Chen Y. Low expression of let-7 predicts poor prognosis in patients with multiple cancers: A meta-analysis. Tumour Biol 2014; 35: 5143–8.
Wu KL, Tsai YM, Lien CT, Kuo PL. The roles of microRNA in lung cancer. Int J Mol Sci 2019; 20 (7): 1611–36.
Wang R, Li G, Zhuang G, et al. Overexpression of microRNA-423–3p indicates poor prognosis and promotes cell proliferation, migration, and invasion of lung cancer. Diagnostic Pathol 2019; 14 (1): 53–61.
Barshack I, Lithwick-Yanai G, Afek A, et al. MicroRNA expression differentiates between primary lung tumors and metastases to the lung. Pathology 2010; 206: 578–84.
Xiao W, Zhong Y, Wu L, et al. Prognostic value of microRNAs in lung cancer: A systematic review and meta-analysis. Mol Clin Oncol 2019; 10 (1): 67–77.
Heneghan HM, Miller N, Lowery AJ, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010; 251 (3): 499–505.
Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol 2010; 119 (3): 586–93.
Zheng R, Pan L, Gao J, et al. Prognostic value of mir-106b expression in breast cancer patients. J Surg Res 2015; 195 (1): 158–65.
Asaga S, Kuo C, Nguyen T, et al. Direct serum assay for microrna-21 concentrations in early and advanced breast cancer. Clin Chem 2011; 57 (1): 84–91.
Al-Khanbashi M, Caramuta S, Alajmi AM, et al. Tissue and serum mirna profile in locally advanced breast cancer (labc) in response to neo-adjuvant chemotherapy (NAC) treatment. PLoS One 2016; 11 (4): e0152032.
Hessvik NP, Sandvig K, Llorente A. Exosomal miRNAs as biomarkers for prostate cancer. Front Genet 2013; 4: 36–45.
Lodes MJ, Caraballo M, Suciu D, et al. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS ONE 2009; 4: e6229.
Guo X, Han T, Hu P, et al. Five microRNAs in serum as potential biomarkers for prostate cancer risk assessment and therapeutic intervention. Int Urol Nephrol 2018; 50 (12): 2193–200.
Chen L, Lü MH, Zhang D, et al. MiR-1207–5p and miR-1266 suppress gastric cancer growth and invasion by targeting telomerase reverse transcriptase. Cell Death Dis 2014; 5 (1): e1034.
Wang H, Wang L, Wu Z, et al. Three dysregulated microRNAs in serum as novel biomarkers for gastric cancer screening. Med Oncol 2014; 31 (12): 298–305.
Kim SY, Jeon TY, Choi CI, et al. Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. J Mol Diagnost 2013; 15 (5): 661–9.
Brenner B, Hoshen MB, Purim O, et al. MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol 2011; 17: 3976–85.
Tang GH, Tang M, Xie YJ. The role of miRNAs in gastric cancer. J Gastroint Dig Syst 2013; 3 (129): 2161–9.
Yazici H. Functions of miRNAs in the development, diagnosis, and treatment of ovarian carcinoma. In Curr Trends Cancer Management. IntechOpen 2019; 66099: 1–17.
Elghoroury EA, ElDine HG, Kamel SA, et al. Evaluation of miRNA-21 and miRNA Let-7 as prognostic markers in patients with breast cancer. Clin Breast Cancer 2018; 18 (4): e721–6.
Sozzi G, Boeri M, Rossi M, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol 2014; 32 (8): 768–73.
Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol 2013; 31 (7): 577 (doi: 10.1038/nbt0713–577).
Zhou X, Huang Z, Xu L, et al. A panel of 13-miRNA signature as a potential biomarker for predicting survival in pancreatic cancer. Oncotarget 2016; 7 (43): 69616.
Shimomura A, Shine S, Kawauchi J, et al. MiniSY-5–4A novel combination of serum microRNAs for detecting breast cancer and predicting efficacy of treatment. Ann Oncol 2016; 27: 53.
Ponomaryova AA, Morozkin ES, Rykova EY, et al. Dynamic changes in circulating miRNA levels in response to antitumor therapy of lung cancer. Exp Lung Res 2016; 42 (2): 95–102.
Qu J, Li M, Zhong W, Hu C. Competing endogenous RNA in cancer: a new pattern of gene expression regulation. Int J Clin Exp Med 2015; 8 (10): 17110.
Lili LN, Huang AD, Zhang M, et al. Time-course analysis of microRNA-induced mesenchymal-to-epithelial transition underscores the complexity of the underlying molecular processes. Cancer Lett 2018; 428: 184–91.
